Affimed NV (NASDAQ:AFMD)

2.79
BATS BZX Real-Time Price
As of 1:14pm ET
 -0.005 / -0.18%
Today’s Change
2.23
Today|||52-Week Range
8.64
-49.46%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$396.9M

Company Description

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Contact Information

Affimed NV
Technologiepark
Heidelberg Baden Wuerttemberg 69120
P:496221674360
Investor Relations:
(917) 436-8102

Employees

Shareholders

Other institutional33.77%
Mutual fund holders17.09%
Individual stakeholders--

Top Executives

Adolf HoessChief Executive Officer
Wolfgang FischerChief Operating Officer
Angus W. SmithChief Financial Officer
Andreas HarstrickChief Medical Officer
Arndt SchotteliusChief Scientific Officer